Aviva PLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 31,427 shares of the biotechnology company's stock, valued at approximately $539,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. Perpetual Ltd bought a new stake in shares of ADMA Biologics during the 4th quarter worth $62,300,000. Lord Abbett & CO. LLC bought a new position in ADMA Biologics in the 3rd quarter worth about $61,858,000. Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after acquiring an additional 2,613,482 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of ADMA Biologics in the fourth quarter worth $19,076,000. Finally, Principal Financial Group Inc. boosted its position in shares of ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after acquiring an additional 1,059,394 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.
View Our Latest Stock Report on ADMA
ADMA Biologics Stock Down 0.9 %
Shares of NASDAQ ADMA traded down $0.19 during trading on Thursday, reaching $21.04. The company had a trading volume of 922,637 shares, compared to its average volume of 3,598,243. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.97 billion, a PE ratio of 75.36 and a beta of 0.53. ADMA Biologics, Inc. has a 12-month low of $5.97 and a 12-month high of $23.64. The business's 50-day moving average is $18.05 and its 200 day moving average is $18.21.
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Recommended Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
